This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kehat, I. Articles by Gepstein, L. Search for Related Content PubMed PubMed Citation Articles by Kehat, I. Articles by Gepstein, L. Related Collections Related Article

(Circulation Research. 2007;101:433.)
© 2007 American Heart Association, Inc.

Editorials

Electrophysiological Coupling of Transplanted Cardiomyocytes

Izhak Kehat, Lior Gepstein

From the Sohnis Laboratory for Cardiac Electrophysiology and Regenerative Medicine (L.G.), and the Bruce Rappaport Faculty of Medicine (I.K., L.G.), Technion-Israel Institute of Technology, Haifa, Israel.

Correspondence to Lior Gepstein, MD, PhD, Technion’s Faculty of Medicine, POB 9649, Haifa, 31096, Israel. E-mail mdlior@tx.technion. ac.il

See related article, pages 484–492

Key Words: cell transplantation • electrical coupling • myogenesis • action-potential

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The recent advances in stem cell biology and tissue engineering have paved the way to the development of a new field in biomedicine, regenerative medicine. This approach seeks to circumvent the shortage of organs for transplantation, by combining the above-mentioned technologies in an attempt to replace diseased or absent tissue. The heart represents an attractive candidate for these emerging technologies, and myocardial cell replacement therapy and tissue engineering present exciting new possibilities for assisting the failing myocardium.^1,2

Despite the enormous enthusiasm associated with cardiovascular regenerative medicine, several obstacles need to be overcome before such strategies can become a clinical reality. Among the major targets that must be achieved are the needs to find an efficient cell source, which will provide the large number of cardiomyocytes required, overcoming the immune rejection barrier of nonautologous cell sources, and finding means for directing stem cells to differentiate to the cardiomyocyte lineage. Yet, concentration on these "major" unanswered questions may lead one to believe that all other issues with cell therapy have been solved. A closer inspection, however, reveals that this is not the case and many questions still remain open. Even if we could identify the ideal stem cell source, could direct the differentiation of these cells efficiently to cardiomyocytes, and prevent immune rejection we still do not know how many cells should be transplanted, what is the best timing and sites for cell transplantation, and most importantly whether the engrafted cells would survive and integrate appropriately with the existing cell-network of host . . . [Full Text of this Article]

Related Article:

Electrophysiological Maturation and Integration of Murine Fetal Cardiomyocytes After Transplantation

Marcel Halbach, Kurt Pfannkuche, Frank Pillekamp, Agnieszka Ziomka, Tobias Hannes, Michael Reppel, Juergen Hescheler, and Jochen Müller-Ehmsen
Circ. Res. 2007 101: 484-492. [Abstract] [Full Text] [PDF]